What is William Blair’s Estimate for TENX Q1 Earnings?

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Stock analysts at William Blair issued their Q1 2026 earnings per share estimates for Tenax Therapeutics in a research note issued to investors on Wednesday, March 26th. William Blair analyst M. Phipps expects that the specialty pharmaceutical company will post earnings per share of ($0.23) for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share. William Blair also issued estimates for Tenax Therapeutics’ Q2 2026 earnings at ($0.24) EPS, Q3 2026 earnings at ($0.23) EPS and Q4 2026 earnings at ($0.24) EPS.

Tenax Therapeutics (NASDAQ:TENX) last released its quarterly earnings data on Tuesday, March 25th. The specialty pharmaceutical company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.34.

Several other brokerages also recently issued reports on TENX. StockNews.com began coverage on shares of Tenax Therapeutics in a research report on Friday, March 21st. They issued a “sell” rating for the company. Leerink Partners set a $20.00 target price on shares of Tenax Therapeutics in a research note on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Tenax Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $18.00.

Tenax Therapeutics Stock Performance

TENX stock opened at $6.18 on Thursday. The firm has a market cap of $24.50 million, a P/E ratio of -1.16 and a beta of 2.20. Tenax Therapeutics has a 1 year low of $2.77 and a 1 year high of $7.89. The stock has a 50-day simple moving average of $6.43 and a 200-day simple moving average of $5.40.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of TENX. Janus Henderson Group PLC acquired a new stake in Tenax Therapeutics in the fourth quarter valued at $1,026,000. Vestal Point Capital LP acquired a new position in Tenax Therapeutics in the third quarter valued at approximately $288,000. Stonepine Capital Management LLC bought a new position in shares of Tenax Therapeutics during the third quarter valued at approximately $173,000. Sphera Funds Management LTD. acquired a new stake in shares of Tenax Therapeutics during the 3rd quarter worth approximately $101,000. Finally, Millennium Management LLC bought a new stake in shares of Tenax Therapeutics in the 4th quarter worth approximately $166,000. Hedge funds and other institutional investors own 1.67% of the company’s stock.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.